Mobile Chat Messaging Enhances Long-Term Smoking Abstinence: JAMA
Written By : Dr. Shravani Dali
Published On 2026-01-23 17:15 GMT | Update On 2026-01-23 17:15 GMT
Advertisement
Researchers have found in a new study that integrating mobile chat–based messaging into existing smoking cessation programs supports relapse prevention and can improve long-term abstinence rates. This highlights a scalable digital strategy to strengthen smoking cessation treatment outcomes.
Most individuals attempting smoking cessation relapse, even with evidence-based treatment. Mobile interventions offer a potential but largely untested strategy to sustain cessation. A study was done to test the effectiveness of mobile chat messaging for relapse prevention among individuals who recently quit smoking. This randomized clinical trial was conducted from March 14, 2023, to August 15, 2024, at 2 clinic-based smoking cessation services in Hong Kong. Participants were adults who smoked daily and had abstained for 3 to 30 days; they were randomly assigned to an intervention group or a control group. All participants received usual smoking cessation treatment from the services. The intervention group additionally received 3 months of mobile relapse prevention intervention, including chat-based support delivered by a live counselor and access to a supportive chatbot via a messaging app. The control group received 8 text messages on generic smoking cessation advice over 3 months as a contact control. The primary outcome was biochemically validated tobacco abstinence at 6 months after randomization, defined by an exhaled carbon monoxide level of less than 5 ppm or a negative salivary cotinine test result. Secondary outcomes at 6 months included self-reported prolonged abstinence, 7-day point prevalence abstinence, and relapse (7 consecutive days of smoking) rate. Intention-to-treat analyses were conducted, assuming participants with missing outcomes relapsed. Results Of 590 participants, 465 (78.8%) were male, and the mean (SD) age was 47.1 (11.2) years; 294 were randomized to the intervention group and 296 were randomized to the control group. The retention rate at 6-month follow-up was 98.0% (n = 578). Biochemically validated abstinence at 6 months was significantly higher in the intervention group than in the control group (45.9% [135 of 294] vs 35.5% [105 of 296]; relative risk [RR], 1.29; 95% CI, 1.06-1.58; P = .01). The intervention group also reported significantly higher prolonged abstinence (57.5% [169 of 294] vs 47.6% [141 of 296]; RR, 1.21; 95% CI, 1.03-1.41; P = .02), higher 7-day point prevalence abstinence (65.6% [193 of 294] vs 54.7% [162 of 296]; RR, 1.20; 95% CI, 1.05-1.37; P = .007), and lower relapse rate (33.0% [97 of 294] vs 44.9% [133 of 296]; RR, 0.73; 95% CI, 0.60-0.90; P = .003) at 6 months. This randomized clinical trial found that mobile chat messaging for smoking relapse prevention increased validated abstinence by approximately 30%, offering a scalable approach to sustain abstinence among individuals who recently quit smoking.
Reference:
Luk TT, Su X, Wong V, et al. Mobile Chat Messaging for Smoking Relapse Prevention: A Randomized Clinical Trial. JAMA Intern Med. Published online January 20, 2026. doi:10.1001/jamainternmed.2025.7439
Keywords:
Mobile, Chat, Messaging, Enhances, Long-Term, Smoking Abstinence, JAMA, Luk TT, Su X, Wong V
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.